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1. Data {#sec1}
=======

The band densities quantification of Western Blotting was shown in the graph below. In [Fig. 1](#fig1){ref-type="fig"}a, Representative blots of p-p38, p-p44/42, p44/42, and beta-actin of the cells after exposing to MG (400 μM) after the treatment time intervals between 1 h and 24 h. Phosphorylation of p38 and p44/42 were induced by MG in RAW264.7 cells. Endogenous p44/42 and beat-actin were used as the internal control. Data shown was corresponding to 5 repeated experiments.Fig. 1The band densities quantification of Western Blotting was shown in the graph. In Fig. 1(a), Representative blots of p-p38, p-p44/42, p44/42, and beta-actin of the cells after exposing to MG (400 μM) after the treatment time intervals between 1 h and 24 h. Phosphorylation of p38 and p44/42 were induced by MG in RAW264.7 cells. Endogenous p44/42 and beat-actin were used as the internal control. Data shown was corresponding to 5 repeated experiments.Fig. 1

In [Fig. 1](#fig1){ref-type="fig"}b, the mRNA expression of osteoclast biomarkers: TRACP5, OSCAR, and CTSK still increased in MG group and the effects of MG did not countered by the transfection. Before 400 μM MG treatment, RAW264.7 cells underwent transfection under treatment of 10 nM siRNA for 24 h. The cells were collected after 24 h MG treatment. However, the mRNA expression of the osteoclast bone biomarkers persisted to increase under p38 and p44/42 inhibition in MG-treated macrophages. Beta-actin acted as mRNA internal control. Data shown was corresponding to 5 repeated experiments.

These data implied that MG activated the p38 and p44/42, which was reported to regulate proliferation and differentiation of osteoclast. However, the decreasing MAPK though siRNA knockdown did not change expression of those target markers, TRACP5, OSCAR, and CTSK, in mRNA level. The effects of MG to other osteoclast markers through p38 and p44/42 would be worth to be investigated.

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Chemicals {#sec2.1}
--------------

Methylglyoxal was purchased from Sigma (St. Louis, MO, USA). *Anti*-β-actin antibody was purchased from Sigma (St. Louis, MO, USA). Lipofectamine® 2000 Transfection Reagent and siRNA were both obtained from Invitrogen (Carlsbad, CA, USA). Remaining antibodies that were used in this study were ordered from Cell Signaling Technology (Beverly, MA, USA). Other chemicals of reagent-grade quality were obtained from Sigma (St. Louis, MO, USA).

2.2. RAW264.7 treatments and cell cultures {#sec2.2}
------------------------------------------

In the study of the cell model, a transfect-able macrophage cell line with the capacity to form osteoclast-like cells, RAW264.7 macrophages (ATCC, TIB-71), was employed. RAW264.7 were cultured in DMEM supplemented with 10% fetal bovine serum, and 1% antibiotic-antimycotic (Invitrogen, Carlsbad, CA, USA) at a humidified atmosphere with 5% CO~2~ at 37 °C. Cells were seeded on 96 and 6 well plates respectively for experimental use. To conduct MTT assay, 24 hours after cell seeding on 96 well plates, cells were treated with MG or vehicle control for 24 hours. For the 6 wells plates, cells were treated with MG and collected at different time intervals (1 h, 3 h, 6 h and 24 h) after the MG treatment. After that, proteins and mRNA of cells were collected for further studies. To conduct experiments of inhibiting p38 and p44/42, cells were treated with 10 nM p38 (MAPK14) and p44/42 (MAPK3) siRNA in Opti-MEM reduced serum culture medium respectively for 24 h before MG treatment. For the negative control, siRNA was added onto cells in Opti-MEM reduced serum culture medium for 24 h before MG treatment. After transfection, cells were treated in MG (400 μM) for 24 h. After that, mRNA of cells was extracted for further studies.

2.3. Western Blotting analysis {#sec2.3}
------------------------------

Proteins from the cells were extracted with radioimmunoprecipitation assay buffer (RIPA) with protease inhibitors containing Complete Mini™ protease inhibitor cocktail (Roche), 1 mM PMSF, and 1 mM Na~2~VO~4~. Protein samples were then separated by SDS-PAGE gel and transferred to the PVDF Western Blotting membrane. The membranes were later probed with respective primary antibodies overnight at 4 °C, and then respective HRP-conjugated secondary antibodies for 1 h. The membranes were incubated with ECL reagents and stained protein bands were exposed and captured using Bio-Rad ChemiDoc Touch Imaging System. The intensities of the protein bands were quantified using Image J, an image-processing program.

2.4. mRNA extraction and real-time PCR {#sec2.4}
--------------------------------------

The endogenous mRNA in cell samples was extracted, using Trizol (Invitrogen). The mRNA was then converted into complementary DNA (cDNA) under reverse transcription. Expressions of the osteoclast biomarkers were assessed by real-time PCR with respective primers:1)Mouse CTSK (F: CCCTTAGTCTTCCGCTCACA, R: TCCTCCGGAGACAGAGCAAA);2)Mouse OSCAR (F: GTCCTGTCGCTGATACTCCAG, R: CCCAGTCTGTCTTGCGGTAG);3)Mouse TRACP5 (F: GCAGCTCCCTAGAAGATGGAT, R: AACACGTCCTCAAAGGTCTCC);4)Mouse β-Actin (F: TAGGCGGACTGTTACTGAGC, R: TGCTCCAACCAACTGCTGTC).

2.5. Statistical test {#sec2.5}
---------------------

Results were shown as means ± standard deviation (SD). The data were processed using Student\'s t-test and one-way analysis of variance (ANOVA) followed by Tukey\'s range test. While P \< 0.05 was considered statistically significant (\*p \< 0.05 in comparison to the control. \*\*p \< 0.01 in comparison to the control).
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